Association of rs738409 Polymorphism in Adiponutrin Gene with Liver Steatosis and Atherosclerosis Risk Factors in Greek Children and Adolescents
- PMID: 36079710
- PMCID: PMC9459993
- DOI: 10.3390/nu14173452
Association of rs738409 Polymorphism in Adiponutrin Gene with Liver Steatosis and Atherosclerosis Risk Factors in Greek Children and Adolescents
Abstract
Non-alcoholic fatty liver disease (NAFLD) shares several risk factors with atherosclerosis, as it is associated with components of the metabolic syndrome. However, genetic variations have also been linked to the risk of NAFLD, such as adiponutrin/patatin-like phospholipase domain-containing the protein 3 (PNPLA3) rs738409 polymorphism. The aim of the study was to determine the associations of thePNPLA3 rs738409 polymorphism with NAFLD and atherosclerosis risk factors in children and adolescents from northern Greece. A total of 91 children/adolescents who followed a Mediterranean eating pattern with no particular restrictions were studied. They were divided into three subgroups, according to their body mass index (BMI) and the presence or absence of liver disease. Diagnosis of NAFLD was based on a liver ultrasound, while the distribution of the PNPLA3 rs738409 polymorphism was investigated in all the participants. From the components of metabolic syndrome, only BMI, waist circumference, blood pressure, and the homeostasis model of insulin resistance (HOMA-IR) differed significantly between groups. The rs738409 polymorphism was significantly associated with BMI and NAFLD, while lipid values had no significant association with either NAFLD or gene polymorphism. This study shows that in Greekchildren, there is a significant association between the rs738409polymorphism in the PNPLA3 gene and hepatic steatosis, regardless of bodyweight.
Keywords: children; dyslipidemia; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; patatin-like phospholipase domain-containing 3 genotype.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- Kavey R.E., Allada V., Daniels S.R., Hayman L.L., McCrindle B.W., Newburger J.W., Parekh R.S., Steinberger J., American Heart Association Expert Panel on Population and Prevention Science. American Heart Association Council on Cardiovascular Disease in the Young et al. Cardiovascular risk reduction in high-risk pediatric patients: A scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics. J. Cardiovasc. Nurs. 2007;22:218–253. - PubMed
-
- Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. National Heart, Lung, and Blood Institute Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report. Pediatrics. 2011;128((Suppl. S5)):S213–S256. doi: 10.1542/peds.2009-2107C. - DOI - PMC - PubMed
-
- Xia M.F., Ling Y., Bian H., Lin H.D., Yan H.M., Chang X.X., Li X.-M., Ma H., Wang D., Zhang L.-S., et al. I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders. Aliment. Pharmacol. Ther. 2016;43:631–642. doi: 10.1111/apt.13521. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
